ARTICLE | Clinical News
Bosulif: Ph III BFORE data
December 21, 2016 12:40 AM UTC
Top-line data from the open-label, international Phase III BFORE trial in 536 patients with chronic phase Ph+ CML showed that first-line treatment with once-daily 400 mg oral Bosulif met the primary e...